By rray, 25 March, 2024 Compress bleeding sites mechanically if accessible Assess hemodynamic status INR CBC renal fxn and last OAC dose Evaluate and treat for other bleeding risk factors EtOH renal failure interacting meds Treat sx w fluids blood transfusion Treat bleeding caus
By rray, 25 March, 2024 Give idarucizumab B NR or activated PCC C LD if idarucizumab not available Consider hemodialysis but may not be practical due to coagulopathy and hemodynamic instability
By rray, 25 March, 2024 Activated PCC 50 units kg x1 Onset 30min Duration 12h Coagulation parameters don t correlate w efficacy Not effective to reverse factor Xa inhibitors
By rray, 25 March, 2024 Idarucizumab 5 g 2 separate vials of 2 5 g vial IV over 5min Additional 5 g may be given if reappearance of bleeding w elevated coagulation parameters or if 2nd emergency surgery procedure required and elevated coagulation parameters Onset 5min Duration 1
By rray, 25 March, 2024 Compress bleeding sites mechanically if accessible Assess hemodynamic status CBC renal fxn and last OAC dose Consider checking diluted thrombin time aPTT ecarin clotting time or ecarin chromogenic assay for dabigatran Some tests not readily available and